Labiotech.eu

News and Trends 20 Dec 2017

British Gene Therapy Gets a Huge £85M Boost in Series B

Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […]

December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […]

December 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 20 Dec 2017

Christmas Has Come Early for Nordic Biotechs as a Norwegian Fund Readies €100M Injection

Hadean Ventures has closed its first fund, which it will begin to invest in life sciences companies around Europe, particularly in the Nordic region. Hadean Ventures is a VC fund based in Oslo, Norway, with the aim of improving healthcare to help patients that are suffering around the world. The VC has closed Hadean Capital […]

December 20, 2017 - 2 minutesmins - By Alex Dale

News and Trends 20 Dec 2017

How to Deal with Regulations to Get Approval for CAR-T Cells

The biotech industry is diving into the field of highly individualized gene and cell therapy products. The first CAR-T therapy has just been approved in the US and other breakthrough technologies like mRNA and CRISPR have a foot in the door. But getting to the market is not straightforward, not only for developers but also for […]

December 20, 2017 - 8 minutesmins - By Timothé Cynober

News and Trends 19 Dec 2017

Belgian Biotech and Roche Take on Neurological and Developmental Disorders

Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […]

December 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Dec 2017

This Gene Therapy for Hemophilia Can Reduce Bleeding by 70%

UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective for years and lets patients stop weekly replacement therapy. From its headquarters in Amsterdam, uniQure is developing what could be one of the first gene therapies for hemophilia. A publication in the journal Blood yesterday details the results of a […]

December 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2017

Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner

Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim signing collaborations with Autifony and Evox Therapeutics. In the last couple of days, Boehringer Ingelheim has agreed to collaborate with two exciting British biotechs. On Monday, a deal worth up to €627.5M was agreed with CNS disorders specialist, […]

December 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 19 Dec 2017

Giving Molecular Combing the Golden Coat It Deserves

The novel spin given to some traditional and established technologies can be astounding. They might have been around for decades, applied in the same way over and over again, and yet, at some point, somebody comes along, observes it in a new light and gives it a brand new polish. One such technology is called […]

December 19, 2017 - 5 minutesmins - By External Contributor

Best in Biotech 19 Dec 2017

Labiotech’s Favorite Biotechs: Which companies do we like and why?

We’ve already named the best companies of the year, but which are our favorite companies? Here’s who they are and why! We tried to be objective when we went through the best companies (as well as the best and worst clinical moments) of the year, but we still have our soft spots. When I asked the […]

December 19, 2017 - 4 minutesmins - By Evelyn Warner

granulomatous disease orchard therapeutics

News and Trends 18 Dec 2017

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Orchard Therapeutics has licensed a gene therapy for the rare genetic disorder X-linked chronic granulomatous disease (X-CGD) from the non-profit Généthon. London-based Orchard Therapeutics is adding a new program to its pipeline of gene therapies. The company has obtained an exclusive license to a lentiviral vector to treat X-linked chronic granulomatous disease and the clinical trial data […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Dec 2017

Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval

An EMA committee has supported an allogeneic stem cell therapy for the first time, as TiGenix’s Crohn’s disease candidate is backed for approval. TiGenix and its Japanese partner, Takeda, are developing a stem cell therapy for Crohn’s disease – an autoimmune disease affecting the gastrointestinal tract. This morning, the companies have revealed that their candidate, Cx601, has received the backing […]

December 18, 2017 - 3 minutesmins - By Alex Dale

hpv cancer isa pharmaceuticals regeneron

News and Trends 18 Dec 2017

Dutch and US Biotechs Team Up Against HPV-related Cancer

ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […]

December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

British Gene Therapy Gets a Huge £85M Boost in Series B

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Christmas Has Come Early for Nordic Biotechs as a Norwegian Fund Readies €100M Injection

How to Deal with Regulations to Get Approval for CAR-T Cells

Belgian Biotech and Roche Take on Neurological and Developmental Disorders

This Gene Therapy for Hemophilia Can Reduce Bleeding by 70%

Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner

Giving Molecular Combing the Golden Coat It Deserves

Labiotech’s Favorite Biotechs: Which companies do we like and why?

British Biotech Takes Over Development of Gene Therapy for Rare Immune Disease

Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval

Dutch and US Biotechs Team Up Against HPV-related Cancer

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!